Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May-Jun;24(1):59-81.

CROI 2016: Advances in Antiretroviral Therapy

Barbara S Taylor  1 , Susan A Olender  2 , Hong-Van Tieu  3 , Timothy J Wilkin  4
Affiliations
Review

CROI 2016: Advances in Antiretroviral Therapy

Barbara S Taylor et al. Top Antivir Med. 2016 May-Jun.

Abstract

The 2016 Conference on Retroviruses and Opportunistic Infections highlighted exciting advances in antiretroviral therapy, including important data on investigational antiretroviral drugs and clinical trials. Clinical trials demonstrated benefits from a long-acting injectable coformulation given as maintenance therapy, examined intravenous and subcutaneous administration of a monoclonal antibody directed at the CD4 binding site of HIV-1, and provided novel data on tenofovir alafenamide. Several studies focused on the role of HIV drug resistance, including the significance of minority variants, transmitted drug resistance, use of resistance testing, and drug class-related resistance. Novel data on the HIV care continuum in low- and middle-income settings concentrated on differentiated HIV care delivery models and outcomes. Data on progress toward reaching World Health Organization 90-90-90 targets as well as outcomes related to expedited initiation of HIV treatment and adherence strategies were presented. Results from a trial in Malawi showed reduced rates of mother-to-child transmission among HIV-infected women who initiated antiretroviral therapy prior to pregnancy, and several studies highlighted the effect of antiretroviral therapy in pediatric populations. A special session was dedicated to the findings of studies of Ebola virus disease and treatment during the outbreak in West Africa.

PubMed Disclaimer

Conflict of interest statement

Financial affiliations in the past 12 months: Drs Olender and Taylor have no relevant financial affiliations to disclose. Dr Tieu has received research grants paid to her institution from Merck & Co, Inc. Dr Wilkin has received research grants paid to his institution from Bristol-Myers Squibb and Gilead, Sciences, Inc. Dr Wilkin’s spouse was an employee of and has stock options from Johnson & Johnson.

References

    1. Varghese V, Wang E, Babrzadeh F, et al. Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutation. PLoS One. 2010;5(6):e10992. - PMC - PubMed
    1. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4(3):e4724. - PMC - PubMed
    1. Stanford University HIV Drug Resistance Database. Calibrated population resistance tool. http://cpr.stanford.edu/cpr.cgi. Accessed on April 15, 2016.
    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/contentfiles/lvguide-lines/adultandadolescentgl.pdf. Accessed on May 31, 2016.
    1. Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society–USA panel. JAMA. 2014;312(4):410-425. - PubMed

Substances

LinkOut - more resources